Objective: To evaluate the efficacy and adverse effects of a biological drug in patients with moderate-to-severe common psoriasis. Subjects and methods: A retrospective cross-sectional descriptive study; 18 patients with moderate-to-severe common psoriasis; guselkumab was administered at standard doses at weeks 0, 4, and 12. Efficacy and adverse effects were evaluated before each injection, from March 2024 to June 2026. Results: At week 12 (after 2 injections), 100% achieved PASI 75, with 44.44% (n=8) achieving PASI 90 and 11.11% (n-2) achieving PASI 100; 72.22% achieved DLQI 0/1. There were no serious adverse effects, with only 5.56% (n=1) experiencing local inflammation. The most common reason for treatment discontinuation was economic 5.56% (n=1). Conclusion: guselkumab is an effective, long-lasting, and safe treatment for moderate to severe common psoriasis.
RESULTS OF TREATMENT OF CONVENTIONAL PSORIASIS WITH GUSELKUMAB AT 19-8 HOSPITAL
0
Views
0
Downloads
Keywords
Bệnh vảy nến, guselkumab
Abstract
References
[1]
1. Lê Thị Hồng Thanh (2020). Nghiên cứu một số yếu tố liên quan và đặc điểm lâm sàng bệnh vảy nến thông thường khám và điều trị tại Bệnh viện Da Liễu Trung ương từ tháng 01/2018 đến tháng 12/2018. Tạp chí Y dược lâm sàng 108 tập 15 -số 3/2020: 8-11.
Google Scholar
[2]
2. A Blauvelt (2017). Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (VOYAGE 1) ClinicalTrials.gov ID NCT02207231
Google Scholar
[3]
3. Andrew Blauvelt, MD, MBA Kim A. Papp, MD, PhD ∙ Christopher E.M. Griffiths, MD∙ Yaung-Kaung Shen, PhD∙ Shu Li, PhD Alexa B. Kimball, MPH, MD (2017) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Google Scholar
[4]
4. Bellinato, F et al. Int. J. Mol. Sci. (2022), Could Targeted Pharmacotherapies
Google Scholar
[5]
Exert a "Disease Modification Effect" in Patients with Chronic Plaque
Google Scholar
[6]
Psoriasis?" 2022 Oct 25;23(21):12849. doi: 10.3390
Google Scholar
[7]
5. Ding X, Wang T, Shen T et al (2012). Prevalence of psoriasis in China: A population – based study in six cities. Eur J Dermatol 22 (5): 663-667. Doi: 10.1684/ejd.2012.1802.
Google Scholar
[8]
6. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM (2013). Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol 133 (2): 377-385. Doi: 10.1038/jid.2012.339
Google Scholar
[9]
7. Kristian Reich , Christopher E M Griffiths , Kenneth B Gordon , Michael Song , Bruce Randazzo , Shu Li , Yaung-Kaung Shen , Chenglong Han , Alexa B Kimball , April W Armstrong , Peter Foley Andrew Blauvelt (2017). Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials Reich et al. Br J Dermatol 2021; Epub 09JUN doi: https://doi.org/10.1111/bjd.20568.
Google Scholar
[10]
8. Yiran Chen, Lei wei, Yu Song, Rui Zhang, Le kuai, Bin Li, Ruiping Wang (2023). Life quality among psoriasis patients based on Dermatology Life Quality Index evaluation and its association with psoriasis severity in China: a cross-sectional study 2023 Jul 7;55(1):2231847. doi: 10.1080/07853890.2023.2231847
Google Scholar